

Administrative:

Telehealth visits can impact after hospitalization follow-up care for mental illness 3

Clearing up coding confusion for retinal eye exams (DRE) 4

Register now for our August CME webinars! 6

Digital Tools:

Digital scheduling feature in the Availity portal: the Appointment Scheduler application 7

Submitting prior authorizations is getting easier 9

Pharmacy:

Specialty dose rounding program for certain oncology medications 10

Pharmacy information available on anthem.com 14

Anthem to update formulary lists for commercial health plan pharmacy benefit 15

August 2021 updates for specialty pharmacy are available 15

Specialty dose rounding program for certain non-oncology medications beginning August 1, 2021 16

Immune globulin adjusted body weight dosing program beginning August 1, 2021 17

Medical Policy & Clinical Guidelines:

New clinical guideline: Home Parenteral Nutrition, effective November 1, 2021 19

Transition to AIM Specialty Health Imaging of the heart clinical appropriateness guideline for Computed Tomography to Detect Coronary Artery Calcification 19

Pre-service/prior authorization clinical review update: August 1, 2021 20

Reimbursement Policies:

Reimbursement policy update: claims requiring additional documentation (facility)	21
Reimbursement policy update: Distinct Procedural Service, modifiers 59 and XE, XP, XS, & XU	22
Reimbursement policy update: Virtual Visits (professional and facility)	23
Federal Employee Plan (FEP):	
Change in email submission of service requests for Federal Employee Program® members	23
Medicare:	
Preventing claims denials: shingles vaccine	25
Keep up with Medicare news	26
Medicaid:	
Prior authorization requirement changes effective September 1, 2021: UM AROW 1576	26
Keep up with Medicaid news	30

Anthem Blue Cross and Blue Shield is the trade name of: In Colorado Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. In Connecticut: Anthem Health Plans, Inc. In Georgia: Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. In Indiana: Anthem Insurance Companies, Inc. In Kentucky: Anthem Health Plans of Kentucky, Inc. In Maine: Anthem Health Plans of Maine, Inc. In Missouri (excluding 30 counties in the Kansas City area): RightCHOICE® Managed Care, Inc. (RIT), Healthy Alliance® Life Insurance Company (HALIC), and HMO Missouri, Inc. RIT and certain affiliates administer non-HMO benefits underwritten by HALIC and HMO benefits underwritten by HMO Missouri, Inc. RIT and certain affiliates only provide administrative services for self-funded plans and do not underwrite benefits. In Nevada: Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. dba HMO Nevada. In New Hampshire: Anthem Health Plans of New Hampshire, Inc. HMO plans are administered by Anthem Health Plans of New Hampshire, Inc. and underwritten by Matthew Thornton Health Plan, Inc. In Ohio: Community Insurance Company. In Virginia: Anthem Health Plans of Virginia, Inc. trades as Anthem Blue Cross and Blue Shield in Virginia, and its service area is all of Virginia except for the City of Fairfax, the Town of Vienna, and the area east of State Route 123. In Wisconsin: Blue Cross Blue Shield of Wisconsin (BCBSWI), which underwrites or administers the PPO and indemnity policies and underwrites the out of network benefits in POS policies offered by CompCare or WCIC; CompCare Health Services Insurance Corporation (CompCare) underwrites or administers the HMO policies and Wisconsin Collaborative Insurance Company (WCIC) underwrites or administers Well Priority HMO or POS policies. Independent licensees of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. Use of the Anthem websites constitutes your agreement with our Terms of Use.

Telehealth visits can impact after hospitalization follow-up care for mental illness


Published: Aug 1, 2021 - Administrative

Reductions in missed appointments are significant.

Telehealth visits are having a significant impact on missed appointments according to a study published in [Counselling Psychology Quarterly](#). Prior to transitioning to telehealth, clinicians in the study “Psychotherapy at a public hospital in the time of COVID-19: telehealth and implications for practice,¹” experienced a 14.25% missed appointment rate. After transitioning to telehealth, the missed appointment rate fell to 5.63%.

Rate of missed appointments before and after transitioning to telehealth

The graph below illustrates the changes in the average rate of missed appointments (cancellations and no-show) for each of the eight clinicians in the study between the periods before and after the transition to telehealth.



“While there are a number of limitations to consider regarding this data, [which is further discussed in the study], the statistically significant reduction in missed appointments pre-and-post [digital] transition is striking,” cited in the study report.

Telehealth and telephone visits with members after a behavioral health (BH) inpatient stay meet HEDIS[®] criteria for the measure: Follow-up after Hospitalization for Mental Illness (FUH). With transportation being one of the barriers to after hospitalization follow-up, telehealth visits could be an ideal solution.²

The FUH HEDIS measure evaluates:

- Members (6 years and older) who were hospitalized for treatment of selected mental illness diagnoses and who had a follow-up visit with a mental health practitioner.

Article Attachments

[1264 image.jpg](#)
image/jpeg - 25.73 KB

Two areas of importance for this HEDIS measure are:

1. The percentage of behavioral health inpatient discharges for which the member received follow-up within 7 days after discharge.
2. The percentage of behavioral health inpatient discharges for which the member received follow-up within 30 days after discharge.

These two consecutive follow-up appointments are paramount to positive outcomes as well as meeting this HEDIS measure. Telehealth visits can greatly increase the likelihood of keeping follow-up appointments leading to reduced numbers of rehospitalization and more favorable outcomes for these patients. To learn more about the [FUH HEDIS measure](#), visit the [NCQA website](#).

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

1 [Counselling Psychology Quarterly](#). Psychotherapy at a public hospital in the time of COVID-19: telehealth and implications for practice

<https://www.tandfonline.com/doi/full/10.1080/09515070.2020.1777390>

2 Traveling towards disease: transportation barriers to health care access.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265215/#:~:text=Transportation%20barriers%20are%20often%20cited,and%20thus%20poorer%20health%20outcomes>

1264-0821-PN-NV

URL: <https://providernews.anthem.com/nevada/article/telehealth-visits-can-impact-after-hospitalization-follow-up-care-for-mental-illness-4>

Clearing up coding confusion for retinal eye exams (DRE)

Published: Aug 1, 2021 - Administrative

The Comprehensive Diabetes Care HEDIS[®] Measure Retinal Eye Exam (DRE) values the percent of adult members ages 18 to 75, with diabetes (type 1 and type 2), who had a retinal eye exam during the measurement year.

Changes to 3072F

The definition for the code 3072F (negative for retinopathy) has been redefined to: *Low risk for retinopathy (no evidence of retinopathy in the prior year)*. This can be particularly confusing because it would not be used at the time of the exam. It would be used the following year, along with the exam coding for the current year, to indicate that retinopathy was not present the previous year.

A simpler coding solution

Using these three codes count toward the DRE measurement if they are billed in the current measurement year, **or** the prior year. This means you can submit the appropriate code at the time of the exam, and it covers both years:

- 2023F: Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed; without evidence of retinopathy (DM)
- 2025F: 7 standard field stereoscopic retinal photos with interpretation by an ophthalmologist or optometrist documented and reviewed: without evidence of retinopathy (DM)
- 2033F: Eye imaging validated to match diagnosis from 7 standard field stereoscopic retinal photos results documented and reviewed: without evidence of retinopathy (DM)

For more about diabetic retinopathy, visit [CMS.gov](https://www.cms.gov) or use [this link to read more](#).

Meeting the measurement for all diabetes care

These exams are also important in evaluating the overall health of diabetic patients, as well as meeting the Comprehensive Diabetes Care HEDIS measure:

- Hemoglobin A1c (HbA1c) testing
- HbA1c poor control (>9.0%)
- HbA1c control (<8.0%)
- Retinal Eye exam performed

- Blood Pressure control (<140/90 mm Hg)

Record your efforts in the member's medical records for the HbA1c tests and results, retinal eye exam, blood pressure, urine creatinine test and the estimated glomerular filtration rate test. Meeting the mark and closing gaps in care is key to good health outcomes.

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

1265-0821-PN-NV

URL: <https://providernews.anthem.com/nevada/article/clearing-up-coding-confusion-for-retinal-eye-exams-dre-4>

Register now for our August CME webinars!

Published: Aug 1, 2021 - Administrative



Join us throughout the year in a new Continuing Medical Education (CME) webinar series as we share practices and success stories to overcoming barriers in achieving clinical quality goals, attaining better patient outcomes and improving STARs ratings.

Program objectives:

- Learn strategies to help you and your healthcare team improve your performance across a range of clinical areas.
- Apply the knowledge you gain from the webinars to improve your organization's quality and STARs ratings.

Attendees will receive one CME credit upon completion of a program evaluation at the conclusion of each webinar.

Registration for our August webinars is now available.

Motivating Patients to Adhere to Cervical Cancer Prevention and Screening Recommendations *(presented by American Cancer Society)*

Date: Tuesday, August 3, 2021

Time: 12:00 p.m. ET

Presented by the American Cancer Society (ACS), this webinar will focus on the pandemic's impact on cancer screenings and implications of delayed cervical cancer screenings and will provide tools and tactics to engage and motivate your patients to adhere to ACS prevention and screening recommendations.

10 Best Practices for Improving Pharmacy Quality Measures

Date: Thursday, August 12, 2021

Time: 1:00 p.m. and 3:00 p.m. ET *(two sessions offered)*

This webinar will explain the role of pharmacy quality measures on overall outcomes and offer practical approaches to improving pharmacy quality measures.

6 Ways to Improve Risk Adjustment Documentation Accuracy

Date: Tuesday, August 17, 2021

Time: 12:00 p.m. and 3:00 p.m. ET *(two sessions offered)*

This webinar will offer best practices to documentation and explain how documentation and coding can enhance patient outcomes.

REGISTER HERE for our upcoming clinical quality webinars!

1275-0821-PN-NV

URL: <https://providernews.anthem.com/nevada/article/register-now-for-our-august-cme-webinars-4>

Digital scheduling feature in the Availity portal: the Appointment Scheduler application

Published: Aug 1, 2021 - **Administrative** / Digital Tools

The Appointment Scheduler application in the [Availity portal](#) allows providers to accept online appointment requests. The Appointment Scheduler App gives you secure access to new appointment requests. You'll also receive digital access to the member's ID number, contact information and any special health information.


Article Attachments

[1266 image.jpg](#)

image/jpeg - 117.88 KB

Appointment Scheduler application features:

- Manage appointment requests
- Configure appointment availability
- Notification for new visit requests on your Availity dashboard
- Members are notified directly via text or email once appointment is confirmed



Administrators, administrator assistants and users with the role of “office staff” will have access to the Appointment Scheduler App.

To access Appointment Scheduler, log onto [Availity.com](#) and select Anthem from Payer Spaces. The Appointment Scheduler App will be located in your Applications menu. To learn more about the new App, go to the Custom Learning Center in Availity and keyword search Appointment Scheduler.

1266-0821-PN-NV

Submitting prior authorizations is getting easier

Published: Aug 1, 2021 - **Administrative** / Digital Tools

You may already be familiar with the Availability Authorization app because millions of providers are already using it to submitting prior authorizations for other payers. Anthem is eager to make it available to our providers, too. On August 21, 2021, you can begin using the Availability Authorization app for Anthem prior authorizations. We hope this will make it easier than ever before to submit prior authorization requests to Anthem.

ICR is still available

If you need to refer to an authorization that was submitted through ICR, you will still have access to that information. We've developed a pathway for you to access your ICR dashboard. You will simply follow the prompts provided through the Availability Authorization App.

Innovation in progress

While we enhance the Availability Authorization app to provide you with Anthem-specific information, we are providing access to ICR for:

- Appeals
- Behavioral health authorizations
- FEP authorizations
- Medical specialty Rx

Notices in the Availability Authorization app will guide you through the process for accessing ICR for *Reserved Auth/Appeals* functions.

Training is available

If you aren't already familiar with the Availability Authorization app, training on Availability Authorization submissions and follow-up is available on the following dates.

- August 23, 2021 at 3:30 p.m.
- August 26, 2021 at 1:00 p.m.
- September 22, 2021 at 11:30 a.m.
- September 30, 2021 at 1:30 p.m.

Article Attachments

[1277.jpg](#)

inode/x-empty - 0 KB

You can always log onto [availity.com](https://www.availity.com) and view the webinar at your convenience. From *Help & Training* select *Get Trained* to access the Availity Learning Center. You can use “*AvAuthRef*” for a keyword search or select the *Session* tab to see all upcoming live webinars.

Give it a try!

Accessing the Availity Authorization app is easy. Just log onto [availity.com](https://www.availity.com) and the authorization icon is on the home screen. You can also access the app through the *Patient Registration* tab by selecting *Authorization and Referral*.

1277-0821-PN-NV

URL: <https://providernews.anthem.com/nevada/article/submitted-prior-authorizations-is-getting-easier-2>

Specialty dose rounding program for certain oncology medications

Published: Aug 1, 2021 - **Products & Programs** / Pharmacy

Providers treating members covered by Anthem plans will be asked in selective circumstances to voluntarily reduce the requested dose to the nearest whole vial for over 40 oncology medications (see list below). Reviews for these oncology drugs will continue to be administered by AIM Specialty Health® (AIM).

As part of the online prior authorization process, providers will be asked about the dosage of the medication being requested in pop-up questions:

- Whether or not the recommended dose reduction is acceptable

- If the patient is considered unable to have his or her dose reduced, then a second question will appear asking for the provider's clinical reasoning.

For prior authorization requests made outside of the online AIM Provider Portal (i.e. via phone or fax) the same questions will be asked by the registered nurse or medical director reviewing the request. **Since this program is voluntary, the decision made regarding dose reduction will not affect the final decision on the prior authorization.**

The dose reduction questions will appear only if the originally requested dose is within 10 percent of the nearest whole vial. This threshold is based on the current medical literature and recommendations from the Hematology and Oncology Pharmacists Association (HOPA) it is appropriate to consider dose rounding within 10 percent. [Click here](#) to view the HOPA recommendations.

The voluntary dose reduction program only applies to the specific oncology drugs listed below. Providers can view prior authorization requirements for Anthem members on the [Medical Policy & Clinical UM Guidelines](#) page at [anthem.com](https://www.anthem.com).

Drug Name	HCPCS Code	Drug Name	HCPCS Code
Abraxane (paclitaxel protein-bound)	J9264	Kadcyla (ado-trastuzumab emtansine)	J9354
Actimmune (interferon gamma-1B)	J9216	Kanjinti (trastuzumab-anns)	Q5117
Adcetris (brentuximab vedotin)	J9042	Keytruda (pembrolizumab)	J9271
Alimta (pemetrexed)	J9305	Kyprolis (carfilzomib)	J9047
Asparlas (calaspargase pegol-mknl)	J9118	Lumoxiti (moxetumomab pasudotox-tdfk)	J9313
Avastin (bevacizumab)	J9035	Mvasi (bevacizumab-awwb)	Q5107
Bendeka (bendamustine)	J9034	Mylotarg (gemtuzumab ozogamicin)	J9203
Besponsa (inotuzumab ozogamicin)	J9229	Neupogen (filgrastim)	J1442
Blinicyto (blinatumomab)	J9039	Ogivri (trastuzumab-dkst)	Q5114
Cyramza (ramucirumab)	J9308	Oncaspar (pegaspargase)	J9266
Darzalex (daratumumab)	J9145	Ontruzant (trastuzumab-dttb)	Q5112
Doxorubicin liposomal	Q2050	Opdivo (nivolumab)	J9299
Elzonris (tagraxofusp-erzs)	J9269	Padcev (enfortumab vedotin-ejfv)	J9177

Empliciti (elotuzumab)	J9176	Polivy (polatuzumab vedotin-piiq)	J9309
Enhertu (fam- trastuzumab deruxtecan- nxki)	J9358	Riabni (rituximab-arrx)	Q5123
Erbitux (cetuximab)	J9055	Rituxan (rituximab)	J9312
Erwinase (asparaginase)	J9019	Ruxience (rituximab-pvvr)	Q5119
Ethyol (amifostine)	J0207	Sarclisa (isatuximab- irfc)	J9227
Granix (tbo- filgrastim)	J1447	Sylvant (siltuximab)	J2860
Halaven (eribulin mesylate)	J9179	Trazimera (trastuzumab- qyyp)	Q5116
Herceptin (trastuzumab)	J9355	Treanda (bendamustine)	J9033
Herzuma (trastuzumab- pkrb)	Q5113	Truxima (rituximab- abbs)	Q5115
Imfinzi (durvalumab)	J9173	Vectibix (panitumumab)	J9303
Istodax (romidepsin)	J9315	Yervoy (ipilimumab)	J9228
Ixempra (ixabepilone)	J9207	Zaltrap (ziv- aflibercept)	J9400
Jevtana (cabazitaxel)	J9043	Zirabev (bevacizumab- bvzr)	Q5118

Note: In some plans “dose reduction to nearest whole vial” or another term “waste reduction” may be the term used in benefit plans, provider contracts or other materials instead of or in addition to “dose reduction to nearest whole vial” and in some plans, these terms may be used interchangeably. For simplicity, we will hereafter use “dose reduction (to nearest whole vial).”

Providers should continue to verify eligibility and benefits for all members prior to rendering services.

If you have questions, please call the Provider Service phone number on the back of the member’s ID card.

1245-0821-PN-NV

URL: <https://providernews.anthem.com/nevada/article/specialty-dose-rounding-program-for-certain-oncology-medications-4>

Pharmacy information available on anthem.com

Published: Aug 1, 2021 - **Products & Programs** / Pharmacy

For more information on copayment/coinsurance requirements and their applicable drug classes, drug lists and changes, prior authorization criteria, procedures for generic substitution, therapeutic interchange, step therapy or other management methods subject to prescribing decisions, and any other requirements, restrictions, or limitations that apply to using certain drugs, visit [anthem.com/pharmacyinformation](https://www.anthem.com/pharmacyinformation). The commercial and marketplace drug lists are posted to the web site quarterly (the first of the month for January, April, July and October).

To locate “Marketplace Select Formulary” and pharmacy information, scroll down to “Select Drug Lists.” This drug list is also reviewed and updated regularly as needed.

FEP Pharmacy updates and other pharmacy related information may be accessed at [fepblue.org](https://www.fepblue.org) > Pharmacy Benefits.

1250-0821-PN-NV

URL: <https://providernews.anthem.com/nevada/article/pharmacy-information-available-on-anthemcom-102>

Anthem to update formulary lists for commercial health plan pharmacy benefit

Published: Aug 1, 2021 - **Products & Programs** / Pharmacy

Effective with dates of service on and after October 1, 2021, and in accordance with the IngenioRx Pharmacy and Therapeutics (P&T) process, Anthem will update its drug lists that support commercial health plans.

Updates include changes to drug tiers and the removal of medications from the formulary.

Please note, this update does not apply to the Select Drug List and does not impact Medicaid and Medicare plans.

To ensure a smooth member transition and minimize costs, providers should review these changes and consider prescribing a drug on formulary or on a lower tier, if appropriate.

View a summary of changes [here](#).

1270-0821-PN-NV

URL: <https://providernews.anthem.com/nevada/article/anthem-to-update-formulary-lists-for-commercial-health-plan-pharmacy-benefit-16>

August 2021 updates for specialty pharmacy are available

Published: Aug 1, 2021 - **Products & Programs** / Pharmacy

Material adverse change: prior authorization updates

Effective for dates of service on and after November 1, 2021, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our prior authorization review process.

Please note, inclusion of National Drug Code (NDC) code on your claim will help expedite claim processing of drugs billed with a Not Otherwise Classified (NOC) code.

To access the Clinical Criteria information, click [here](#).

Prior authorization clinical review of non-oncology use of specialty pharmacy drugs is managed by the medical specialty drug review team. *Review of specialty pharmacy drugs for oncology use is managed by AIM Specialty Health® (AIM).*

Clinical Criteria	HCPCS or CPT Code(s)	Drug
*ING-CC-0196	J3490, J9999, J3590	Zynlonta (loncastuximab tesirine-lpyl)
*ING-CC-0197	J3490, J3590, J9999	Jemperli (dostarlimab)
ING-CC-0199	J3490, J3590, C9399	Empaveli (pegcetacoplan)

* *Oncology use is managed by AIM.*

Quantity limit updates

Effective for dates of service on and after November 1, 2021, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our quantity limit review process.

Clinical Criteria	HCPCS or CPT Code(s)	Drug
ING-CC-0199	J3490, J3590, C9399	Empaveli (pegcetacoplan)

1271-0821-PN-NV

URL: <https://providernews.anthem.com/nevada/article/august-2021-updates-for-specialty-pharmacy-are-available>

Specialty dose rounding program for certain non-oncology medications beginning August 1, 2021

Published: Aug 1, 2021 - **Products & Programs** / Pharmacy

Anthem Blue Cross and Blue Shield (Anthem) is committed to being a valued healthcare partner in identifying ways to achieve better health outcomes, lower costs and deliver access to a better healthcare experience for consumers.

Effective with dates of service on or after August 1, 2021, providers treating members covered by Anthem commercial plans may be asked to consider voluntarily reducing the requested dose to avoid vial wastage for select non-oncology specialty medications. The dose reduction suggestion will only be made if the originally requested dose is within 10% of the nearest whole vial.

Since this program is voluntary, the decision to participate will not affect the final decision on the prior authorization.

Reviews for these specialty drugs will continue to be administered by IngenioRx®.

As part of the prior authorization process, providers may be asked the following questions:

- Whether the suggested dose reduction is clinically acceptable
- Clinical reasoning if the dose reduction is not appropriate

Providers can view prior authorization requirements for Anthem members on the [Medical Policy & Clinical UM Guidelines](#) page at [anthem.com](https://www.anthem.com).

Providers should continue to verify eligibility and benefits for all members prior to rendering services.

If you have questions, please call the provider service phone number on the back of the member's ID card.

1273-0821-PN-NV

URL: <https://providernews.anthem.com/nevada/article/specialty-dose-rounding-program-for-certain-non-oncology-medications-beginning-august-1-2021-2>

Immune globulin adjusted body weight dosing program beginning August 1, 2021

Published: Aug 1, 2021 - **Products & Programs** / Pharmacy

Anthem Blue Cross and Blue Shield (Anthem) is committed to being a valued healthcare partner in identifying ways to achieve better health outcomes, lower costs and deliver access to a better healthcare experience for consumers.

Effective with dates of service on or after August 1, 2021, providers treating members covered by Anthem commercial plans may be asked to consider voluntarily using adjusted body weight (AdjBW) dosing compared to actual body weight (ABW) dosing for immune globulin medications. The dose change using AdjBW will only be made if the member's actual body weight is more than 20% of the ideal body weight (IBW).

Since this program is voluntary, the decision to participate will not affect the final decision on the prior authorization.

Reviews for the immune globulin medications will continue to be administered by IngenioRx® as these will specifically target specialty non-oncology indications.

As part of the prior authorization process, providers may be asked the following questions:

- Whether the suggested use of AdjBW and change in dose is clinically acceptable
- Clinical reasoning if the dose change (using AdjBW) is not appropriate

Providers can view prior authorization requirements for Anthem members on the [Medical Policy & Clinical UM Guidelines](#) page at [anthem.com](https://www.anthem.com).

Providers should continue to verify eligibility and benefits for all members prior to rendering services.

If you have questions, please call the provider service phone number on the back of the member's ID card.

1274-0821-PN-NV

URL: <https://providernews.anthem.com/nevada/article/immune-globulin-adjusted-body-weight-dosing-program-beginning-august-1-2021-3>

New clinical guideline: Home Parenteral Nutrition, effective November 1, 2021

Published: Aug 1, 2021 - **Policy Updates** / Medical Policy & Clinical Guidelines

Anthem Blue Cross and Blue Shield (Anthem) will implement the following clinical guideline, effective November 1, 2021, to support the review for parenteral nutrition given in the home setting

To view the policy for [Home Parenteral Nutrition \(CG-MED-89\)](#).

If you have questions, please call the provider service number on the back of the member's ID card.

1254-0821-PN-NV

URL: <https://providernews.anthem.com/nevada/article/new-clinical-guideline-home-parenteral-nutrition-effective-november-1-2021-1>

Transition to AIM Specialty Health Imaging of the heart clinical appropriateness guideline for Computed Tomography to Detect Coronary Artery Calcification

Published: Aug 1, 2021 - **Policy Updates** / Medical Policy & Clinical Guidelines

Effective November 1, 2021, Anthem Blue Cross and Blue Shield (Anthem) will transition the clinical criteria for medical necessity review of Computed Tomography to Detect Coronary Artery Calcification to AIM imaging of the heart clinical appropriateness guideline.

As part of this transition of clinical criteria, the following procedures will be subject to prior authorization at AIM:

CPT code	Description
75571	Computed tomography, heart, without contrast material, with quantitative evaluation of coronary artery calcium
S8092	Electron beam CT (also known as ultrafast CT, cine CT)

As a reminder, ordering and servicing providers may submit prior authorization requests to AIM in one of several ways:

- Access AIM's **ProviderPortal**SM directly at providerportal.com. Online access is available 24/7 to process orders in real-time, and is the fastest and most convenient way to request authorization.
- Access AIM via the Availity Web Portal at [availity.com](https://www.availity.com)
- Call the AIM Contact Center toll-free number: 877-291-0366, Monday–Friday, 7:00 a.m.–5:00 p.m. PT.

For questions related to guidelines, please contact AIM via email at aim.guidelines@aimspecialtyhealth.com. Additionally, you may access and download a copy of the current and upcoming guidelines [here](#).

1258-0821-PN-NV

URL: <https://providernews.anthem.com/nevada/article/transition-to-aim-specialty-health-imaging-of-the-heart-clinical-appropriateness-guideline-for-computed-tomography-to-detect-coronary-artery-calcification-4>

Pre-service/prior authorization clinical review update: August 1, 2021

Published: Aug 1, 2021 - **Policy Updates** / Medical Policy & Clinical Guidelines

Effective with dates of service on or after November 1, 2021, Anthem Blue Cross and Blue Shield will require review of the below clinical guidelines for medical necessity. Medical

necessity review will require prior authorization. Ordering and servicing providers may submit prior authorization requests by contacting the phone number on the back of the members ID card.

Clinical guideline name and description:

- **CG-DME-06 Pneumatic Compression Devices for Lymphedema:** This document addresses the use of pneumatic compression devices for the treatment of lymphedema. This therapy involves the use of an inflatable garment for various body parts and an electrical pneumatic pump. The garment is intermittently inflated and deflated with cycle times and pressures that vary between devices. Pneumatic compression devices are used in clinics or can be purchased or rented for home use. This document addresses the home use of pneumatic compression devices
- **CG-SURG-93 Angiographic Evaluation and Endovascular Intervention for Dialysis Access Circuit Dysfunction:** This document addresses angiographic evaluation for dialysis access circuit dysfunction and treatment for stenotic or thrombosed arterio-venous grafts (AVG) or fistulas (AVF). This document does not address angiographic evaluation as a treatment for venous thoracic outlet syndrome, superior vena cava syndrome, Budd-Chiari syndrome, congenital cardiac defects, lower extremity venous congestion, or improving venous flow in individuals with multiple sclerosis and chronic cerebrospinal venous insufficiency (CCSVI).

Anthem's [Medical Polices and Clinical UM Guidelines](#) are available online on Anthem's website at [anthem.com/providers](https://www.anthem.com/providers) and can be found using the following path: **Providers > State > Review Policies > View Policies and Guidelines > Medical Policies and Clinical UM Guidelines** (for Local Plan members).

1248-0821-PN-NV

URL: <https://providernews.anthem.com/nevada/article/pre-serviceprior-authorization-clinical-review-update-august-1-2021>

Reimbursement policy update: claims requiring additional documentation (facility)

Published: Aug 1, 2021 - **Policy Updates** / Reimbursement Policies

In the [May edition](#) of [Provider News](#), we announced a threshold increase for the itemized bill

requirement for outpatient facility claims. This requirement will remain; however effective August 1, 2021, Anthem Blue Cross and Blue Shield will remove the threshold amount from the policy language for outpatient facility claims and inpatient stay claims.

For more information about this policy, visit our [Reimbursement Policy](https://www.anthem.com/provider) page at [anthem.com/provider](https://www.anthem.com/provider).

1260-0821-PN-NV

URL: <https://providernews.anthem.com/nevada/article/reimbursement-policy-update-claims-requiring-additional-documentation-facility-35>

Reimbursement policy update: Distinct Procedural Service, modifiers 59 and XE, XP, XS, & XU

Published: Aug 1, 2021 - **Policy Updates** / Reimbursement Policies

Beginning with dates of service on or after November 1, 2021, Anthem Blue Cross and Blue Shield will update the Related Coding section to indicate no modifier override for the neurostimulator device when billed with the surgical code for the implantation of the neurostimulator device.

The code pairs listed below has been added to the Related Coding section:

- L8680 when reported with 63655
- L8679 when reported with 63650
- L8679 when reported with 63655
- L8687 when reported with 63650
- L8687 when reported with 63655

For more information about this policy, visit our [Reimbursement Policy](https://www.anthem.com/provider) page at [anthem.com/provider](https://www.anthem.com/provider).

1261-0821-PN-NV

URL: <https://providernews.anthem.com/nevada/article/reimbursement-policy-update-distinct-procedural-service-modifiers-59-and-xe-xp-xs-xu-6>

Reimbursement policy update: Virtual Visits (professional and facility)

Published: Aug 1, 2021 - **Policy Updates** / Reimbursement Policies

Beginning with dates of service on or after November 1, 2021, Anthem Blue Cross and Blue Shield (Anthem) current Telehealth policy will be renamed Virtual Visits. Anthem allows reimbursement for professional and facility Virtual Visits when interactive services occur between the member and the provider, when they are not in the same location, unless provider, state, or federal contracts and/or mandates indicate otherwise. Reimbursement is allowed for professional and facility Virtual Visits rendered at the distant site via live audio visual services and for remote patient monitoring. In addition, facility Virtual Visits will be allowed for the originating site fee. The related coding section details the modifiers allowed for reimbursement.

For more information about this policy, visit our [Reimbursement Policy](#) page at [anthem.com/provider](https://www.anthem.com/provider).

1267-0821-PN-NV

URL: <https://providernews.anthem.com/nevada/article/reimbursement-policy-update-virtual-visits-professional-and-facility-8>

Change in email submission of service requests for Federal Employee Program® members

Published: Aug 1, 2021 - **State & Federal** / Federal Employee Plan (FEP)

Effective November 1, 2021, in order to help ensure our member's security, the Blue Cross and Blue Shield Federal Employee Program (FEP®) will be decommissioning the Utilization Management (UM) email address for processing eReviews, FEPE-Reviews@anthem.com. **As an alternative**, FEP offers providers a secure online portal, Interactive Care Reviewer (ICR).

About the ICR portal

ICR is Anthem Blue Cross and Blue Shield's (Anthem's) innovative UM portal that allows providers, in addition to phone or fax, to submit prior authorization requests and to provide clinical documentation (including imaging) to support initial and continued stay reviews. This enables prior authorization requests and clinical information to be transmitted directly to UM staff.

Key features of the portal

- No cost electronic UM solution
- Instant access from any location at any time
- Create a UM preauthorization case and instantly submit it for review
- Attach clinical documents for review – no faxing required
- Check status of any case regardless of the method used to originally submit request
- Complete record of submissions and dispositions – all in one place
- Bi-directional communication

To submit prior authorization service requests electronically, register for use of ICR prior to **November 1, 2021** on the [Availity portal](#).

–
For [more information on Anthem ICR, including training resources](#) visit the ICR page of our [anthem.com/provider](#) website.

Register for ICR via the Availity portal

[Click this link to register.](#)

Need assistance registering?

[How to Access Availity and Register](#)

As a reminder, in addition to using ICR on the Availity portal, you can submit authorizations, to FEP UM by phone or fax:

- FEP UM precertification toll free #: 800-860-2156
- FEP UM precertification fax #: 800-732-8318
- FEP UM advance benefit determination fax #: 877-606-3807

1247-0821-PN-NV

Preventing claims denials: shingles vaccine

Published: Aug 1, 2021 - **State & Federal** / Medicare

Medicare Advantage

Know best: Shingles vaccinations are a Medicare Part D benefit whether administered in your office or in the pharmacy

We want you to have the information you need when filing claims for our Medicare Advantage members so your payments are received quickly and effortlessly. The shingles vaccine and the administration of the vaccine is commonly billed in error under the member's Medicare Part B medical benefit. The shingles vaccination is a Medicare Part D pharmacy benefit, which requires the member to pay in advance of reimbursement. The member then submits the prescription drug claim form to their Medicare Part D plan for reimbursement.

You can also refer the member to the pharmacy for the vaccine. The claim is usually filed for the member by the pharmacy provider using a clearinghouse platform that enables Medicare Part D claims transactions. Or, if you have access to clearinghouse platforms that enable you to file pharmacy transactions, that is another option for administering the vaccination in your office and for further serving the member.

The Centers for Medicare & Medicaid Services (CMS) has a helpful resource, *MLN Fact Sheet: Medicare Part D Vaccines*, that offers an all-inclusive look into patient access, vaccine administration, and reimbursement. Use this link to [download a copy](#).

We want you to have all the information you need to know best. For more information about filing claims, [visit this link](#).

ABSCARE-0988-21

Keep up with Medicare news

Published: Aug 1, 2021 - **State & Federal** / Medicare

Medicare Advantage

Please continue to check [Important Medicare Advantage Updates](#) at anthem.com/medicareprovider for the latest Medicare Advantage information, including:

- [Prior authorization requirement changes effective October 1, 2021 – UM AROW 1907](#)
- [Infliximab Step Therapy – Effective July 15, 2021](#)

ABSCRNU-0236-21

ABSCRNU-0241-21

URL: <https://providernews.anthem.com/nevada/article/keep-up-with-medicare-news-215>

Prior authorization requirement changes effective September 1, 2021: UM AROW 1576

Published: Aug 1, 2021 - **State & Federal** / Medicaid

Medicaid

Summary of change

Effective **September 1, 2021**, prior authorization (PA) requirements will change for the following codes. The medical codes listed below will require PA by Anthem Blue Cross and Blue Shield Healthcare Solutions for Nevada Medicaid members. Federal and state law, as well as state contract language and CMS guidelines, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage. **Noncompliance with new requirements may result in denied claims.**

PA requirements will be added to the following:

- 0203U — Autoimmune (inflammatory bowel disease), mRNA, gene expression profiling by quantitative RT-PCR, 17 genes (15 target and 2 reference genes), whole blood, reported as a continuous risk score and classification of inflammatory bowel disease aggressiveness
- 0208U — Oncology (medullary thyroid carcinoma), mRNA, gene expression analysis of 108 genes, utilizing fine needle aspirate, algorithm reported as positive or negative for medullary thyroid carcinoma
- 0230U — Androgen receptor (AR) (for example, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation), full sequence analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions
- 0231U — Calcium voltage-gated channel subunit alpha 1A (CACNA1A) (for example, spinocerebellar ataxia), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, STR gene expansions, mobile element insertions, and variants in non-uniquely mappable regions
- 0232U — Cystatin B (CSTB) (for example, progressive myoclonic epilepsy type 1A, Unverricht-Lundborg disease), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, STR expansions, mobile element insertions, and variants in non-uniquely mappable regions
- 0233U — Frataxin (FXN) (for example, Friedreich ataxia), gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, STR expansions, mobile element insertions, and variants in non-uniquely mappable regions
- 0234U — Methyl CpG binding protein 2 (MECP2) (for example, Rett syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions
- 0235U — Phosphatase and tensin homolog (PTEN) (for example, Cowden syndrome, PTEN hamartoma tumor syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions
- 0236U — Survival of motor neuron 1, telomeric (SMN1) and survival of motor neuron 2, centromeric (SMN2) (for example, spinal muscular atrophy) full gene analysis, including small sequence changes in exonic and intronic regions, duplications and deletions, and mobile element insertions

- 0238U — Oncology (Lynch syndrome), genomic DNA sequence analysis of MLH1, MSH2, MSH6, PMS2, and EPCAM, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions
- 0620T — Endovascular venous arterialization, tibial or peroneal vein, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed
- 33995 — Insertion of ventricular assist device, percutaneous, including radiological supervision and interpretation; right heart, venous access only
- 58999 — Unlisted Proc, Female Genital System (Nonobstetrical)
- 81191 — Neurotrophic receptor tyrosine kinase 1 (NTRK1) (for example, solid tumors) translocation analysis
- 81192 — Neurotrophic receptor tyrosine kinase 2 (NTRK2) (for example, solid tumors) translocation analysis
- 81193 — Neurotrophic receptor tyrosine kinase 3 (NTRK3) (for example, solid tumors) translocation analysis
- 81194 — Neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3 (NTRK) (for example, solid tumors) translocation analysis
- 81279 — Janus kinase 2 (JAK2) (for example, myeloproliferative disorder) targeted sequence analysis (for example, exons 12 and 13)
- 81338 — MPL proto-oncogene, thrombopoietin receptor (MPL) (for example, myeloproliferative disorder) gene analysis; common variants (for example, W515A, W515K, W515L, W515R)
- 81339 — MPL proto-oncogene, thrombopoietin receptor (MPL) (for example, myeloproliferative disorder) gene analysis; sequence analysis, exon 10
- 81351 — Tumor protein 53 (TP53) (for example, Li-Fraumeni syndrome) gene analysis; full gene sequence
- 81352 — Tumor protein 53 (TP53) (for example, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (for example, 4 oncology)
- 81353 — Tumor protein 53 (TP53) (for example, Li-Fraumeni syndrome) gene analysis; known familial variant
- 81546 — Oncology (thyroid), mRNA, gene expression analysis of 10,196 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (for example,

benign or suspicious)

- C1778 — Lead, neurostimulator (implantable)
- C1787 — Patient programmer, neurostimulator
- C1883 — Adaptor/extension, pacing lead or neurostimulator lead (implantable)
- G0068 — Professional services for the administration of anti-infective, pain management, chelation, pulmonary hypertension, and/or inotropic infusion drug(s) for each infusion drug administration calendar day in the individual's home, each 15 minutes
- G0069 — Professional services for the administration of subcutaneous immunotherapy for each infusion drug administration calendar day in the individual's home, each 15 minutes
- G0070 — Professional services for the administration of chemotherapy for each infusion drug administration calendar day in the individual's home, each 15 minutes
- G0088 — Professional services, initial visit, for the administration of anti-infective, pain management, chelation, pulmonary hypertension, inotropic, or other intravenous infusion drug or biological (excluding chemotherapy or other highly complex drug or biological) for each infusion drug administration calendar day in the individual's home, each 15 minutes
- G0089 — Professional services, initial visit, for the administration of subcutaneous immunotherapy or other subcutaneous infusion drug or biological for each infusion drug administration calendar day in the individual's home, each 15 minutes
- G0090 — Professional services, initial visit, for the administration of intravenous chemotherapy or other highly complex infusion drug or biological for each infusion drug administration calendar day in the individual's home, each 15 minutes

To request PA, you may use one of the following methods:

- **Web:** Once logged in to Availity* at [availity.com](https://www.availity.com), select **Patient Registration > Authorizations & Referrals**, then choose **Authorizations** or **Auth/Referral Inquiry**, as appropriate.
- **Fax:** 844-396-2330
- **Phone:** 800-964-3627

Not all PA requirements are listed here. Detailed PA requirements are available to contracted providers the provider website at providers.anthem.com/nv > **Login**. Contracted and noncontracted providers who are unable to access the provider website may call our Provider Services at 844-396-2330 for assistance with PA requirements.

Availity, LLC is an independent company providing administrative support services on behalf of Anthem Blue Cross and Blue Shield Healthcare Solutions.
ANV-NU-0241-21

URL: <https://providernews.anthem.com/nevada/article/prior-authorization-requirement-changes-effective-september-1-2021-um-arow-1576>

Keep up with Medicaid news

Published: Aug 1, 2021 - **State & Federal** / Medicaid

Medicaid

Please continue to check Medicaid Provider Communications & updates at [anthem.com/nymedicaidoc](https://www.anthem.com/nymedicaidoc) for the latest Medicaid information, including:

- [Specialty Rx precertification additional documentation notice effective August 1, 2021](#)
- [Clinical criteria updates notification March 2021](#)
- [2021 annual new code update](#)
- [Medical step therapy — Kesimpta](#)

ANV-NU-0237-21
ANV-NU-0244-21
ANV-NU-0250-21
ANV-NU-0251-21

URL: <https://providernews.anthem.com/nevada/article/keep-up-with-medicaid-news-71>
